Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology
- 5 March 1998
- Vol. 80 (3) , 271-280
- https://doi.org/10.1016/s0300-9084(98)80009-6
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- DNA-Topoisomerase I, a new target for the treatment of neuroblastomaEuropean Journal Of Cancer, 1997
- Cell Cycle–coupled Relocation of Types I and II Topoisomerases and Modulation of Catalytic Enzyme ActivitiesThe Journal of cell biology, 1997
- Phase I Trial and Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Topotecan Using a Five-Day Course in Children with Refractory Solid TumorsJournal of Pediatric Hematology/Oncology, 1996
- Current perspectives on camptothecins in cancer treatmentBritish Journal of Cancer, 1996
- Clinical Pharmacokinetics of TopotecanClinical Pharmacokinetics, 1996
- Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumorsCancer Chemotherapy and Pharmacology, 1995
- Phase I study of topotecan for pediatric patients with malignant solid tumors.Journal of Clinical Oncology, 1994
- Comparative Activity of Oral and Parenteral Topotecan in Murine Tumor Models: Efficacy of Oral TopotecanCancer Investigation, 1994
- Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenograftsCancer Chemotherapy and Pharmacology, 1994
- DNA Topoisomerase I—Targeted Chemotherapy of Human Colon Cancer in XenograftsScience, 1989